NYSE:ABBVBiotechs
What Does AbbVie (ABBV) Need To Prove After Its Phase 3 Setback?
AbbVie (NYSE:ABBV) and Genmab reported that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab in diffuse large B-cell lymphoma did not meet its overall survival primary endpoint.
Epcoritamab retains its current accelerated FDA approval, but the Phase 3 outcome raises regulatory and commercial uncertainty for the oncology asset.
The setback comes alongside other recent AbbVie product news, including FDA acceptance of a new BOTOX Cosmetic application and progress on Canadian reimbursement for...